<DOC>
	<DOCNO>NCT02117661</DOCNO>
	<brief_summary>Obesity one main cause metabolic syndrome , condition become common Canada worldwide . Metabolic syndrome name group heart disease risk factor occur together : obesity , diabetes , high blood pressure , high cholesterol . These patient high risk develop narrowing blockage blood vessel occur fat cholesterol build wall blood vessel form plaque . This call atherosclerosis . Plaque buildup lead stroke , heart attack , death . We understand underlie mechanism metabolic syndrome treatment . L-carnitine , dietary supplement , show treat component metabolic syndrome , benefit reduce plaque blood vessel never study . Recently controversy new study show L-carnitine could make heart disease bad patient . Our goal study whether supplementation L-carnitine fact prevent reduce buildup plaque blood vessel patient metabolic syndrome . This novel therapy potential decrease burden heart disease obese diabetic patient metabolic syndrome .</brief_summary>
	<brief_title>Carnitine Treatment Atherosclerosis .</brief_title>
	<detailed_description>Primary Question : Does L-carnitine ( L-C ) therapy slow and/or regress atherosclerosis , measure total plaque volume ( TPV ) assess 3-dimensional ( 3D ) carotid ultrasound patient metabolic syndrome ? We hypothesize L-C regress atherosclerotic plaque formation . To assess primary outcome L-C induce atherosclerosis regression , anticipate significant percent ( % ) difference carotid total plaque volume ( TPV ) six month L-C treatment , compare placebo . For secondary outcome , expect show L-C therapy compare placebo , induces reduction proportion small-sized LDL increase large LDL particle . As small dense LDL particles atherogenic large buoyant one , would suggest mechanism contribute atherosclerosis reduction induce L-C therapy .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>Study Population : Patients , follow clinic cardiovascular disease ( CVD ) prevention , fulfil diagnosis criterion metabolic syndrome ( MetS ) recruit . Eligibility require 2 step process describe . STEP 1 : Initial screening ; BP , weight fast blood sample obtain . 1 . Men woman , &gt; 18 year , meet criterion clinical diagnosis MetS , accord International Diabetes Federation ( IDF ) harmonize definition , 3 5 follow risk factor cut point constitutes diagnosis MetS : 1 . Elevated waist circumference : Population countryspecific definition ; Health Canada recommend male 102 cm woman 88cm . 2 . Elevated triglyceride : 150 mg/dL ( 1.7 mmol/L ) . 3 . Reduced HDL : 40 mg/dL ( 1.0 mmol/L ) males ; 50 mg/dL ( 1.3 mmol/L ) females treat . 4 . Elevated BP : Systolic 130 and/or diastolic 85 mm Hg treat . 5 . Elevated fast glucose : 100 mg/dL ( 5.6 mmol/L ) , HbA1c ≥6.2 % , treat . 2 . Willing provide inform consent . STEP 2 : Baseline plaque volume ≥50 mm3 3D US , ensure sufficient detectable plaque . This measured consent ( Step 1 ) , prior randomization/enrolment ( Step 2 ) . Exclusion criterion : 1 . Individuals change statin and/or diabetes medication therapy dose last three month ; 2. Who actively unstable arrhythmia , angina heart attack ( untreated and/or unstable patient ) : symptomatic heart failure ( NYHA 2 great ) ; renal failure ( GFR &lt; 50 mL/min/1.73m2 ) ; 3 . Known severe abnormal blood biochemistry : Na &lt; 100 &gt; 150 mmol/L , K &lt; 2 &gt; 5 mmol/L , Total Serum Ca &gt; 3 mmol/L ; 4 . Known severe liver disease : AST &gt; 100 U/L , ALT &gt; 80 U/L , diagnosis cirrhosis ( Child Pugh Class A C ) ; 5 . Known severe anemia : HgB &lt; 70 g/L ; 6 . Have endocrine disorder , e.g . Cushing 's disease , hyper hypothyroidism ; 7 . Any condition expect limit survival less six ( 6 ) month ( ex . malignant tumor ) ; 8 . A condition limit adherence study procedure ( i.e . alcoholism , drug addiction , know poor adherence , severe mental disorder ) ; 9 . Concomitant treatment : anticonvulsant ; LC derivatives ; Acenocoumarol ( Sintrom ) Warfarin ( Coumadin ) anticoagulants vitamin K antagonist ; &gt; 1g fish oil ; and/or thyroid treatment ; 10 . A seizure disorder risk seizure ( CNS mass medication low seizure threshold ) ; receive treatment cancer HIV infection ( secondary LC deficiency ) ; 11 . Currently pregnant breastfeeding ; 12 . A history allergy intolerance LC derivatives ; 13 . Vegetarians ( eat animal flesh ) due potential alter LC metabolism ; 14 . Patients carotid surgery ( ie . endarterectomy ( CEA ) stent ) schedule receive carotid surgery trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>L-carnitine</keyword>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Carotid</keyword>
	<keyword>Plaque</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Heart disease</keyword>
	<keyword>Vascular disease</keyword>
</DOC>